🔗 Share this article

Given that America proceeds with historic changes to its immunization guidelines, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by questioning COVID-19 vaccines during the pandemic and has concentrated on potential deaths after COVID-19 vaccination in her recent position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Schedule

Agency leaders were set to unveil major revisions to the pediatric vaccine schedule earlier this month, bringing the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US at odds with much of the world with insufficient data for improved outcomes. The announcement has been delayed until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is set to present at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this calendar year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad solidify control at the FDA – and it suggests a renewed priority upon dismantling already-approved vaccines at the FDA.

Høeg has often pushed for ending specific childhood shot schedules in the US in order to be more like Denmark, a nation with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccination policy – traditionally the purview of Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Concerns Over Background

The appointee has no obvious background in drug development, approval processes or administrative roles, which has been customary for former heads of the CBER. She has served at the FDA as a senior adviser to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in managing a large organization. She lacks background in pharmaceutical oversight.”

Past commissioners of the center would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who led the center have had.”

The drug center has an vast range of responsibilities at the FDA, the former commissioner emphasized.

“The public just zeroes in on the novel medication approvals, but the generic program authorizes thousands of generic drugs. There is also a biosimilars division, OTC medication office and so forth, and each of these have to be supervised,” Dr. Woodcock noted. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a significant administrative element to the job, which manages in excess of 5,000 staff members. “It is a huge administrative position, if you perform it correctly,” she said.

Official Statement and Contentious Programs

Regarding concerns about Dr. Høeg's qualifications and whether this assignment signifies greater collaboration among agency officials on vaccines, a press secretary stated that the “questions are based on flawed premises”.

“Her resume is consistent with the responsibilities of her job,” the official stated, pointing to the months Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious rapid medication authorization process that reportedly troubled her former heads. “By what process are these therapies being selected for this voucher program? Who takes the calls?” Dr. Howard asked. “There’s a lot of secrecy going on at the agency right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed oversight of all drugs, aside from immunizations.”

Public Past Work on Immunizations

Concerning vaccines, Høeg has a more documented, if concerning, track record, Howard observe. She authored a research paper using non-validated volunteer-provided data to estimate the incidence of myocarditis following COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are more dangerous than they are.

Part of her “policy goals” for the incoming administration encompassed altering guidelines for novel immunizations and halting “unnecessary” vaccines, she stated post-election on a audio program. At the FDA, Høeg has allegedly proposed preventing teenage boys from receiving COVID-19 vaccines.

“She is an complete true believer who starts off with her preconceived notions and works backwards to retrofit the evidence in a extremely disingenuous, untruthful way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|